24F914FE-3DF0-4286-9231-9D525A777306
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 36.530880420499344
- age_years
- 43
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.486
- TGF_BETA_SIGNALING+0.479
- PROTEIN_SECRETION+0.462
- MYC_TARGETS_V1+0.366
- WNT_BETA_CATENIN_SIGNALING+0.363
- MITOTIC_SPINDLE+0.338
- DNA_REPAIR+0.334
- G2M_CHECKPOINT+0.303
- UNFOLDED_PROTEIN_RESPONSE+0.264
- HEDGEHOG_SIGNALING+0.243
Top 10 suppressed
- KRAS_SIGNALING_DN-0.456
- SPERMATOGENESIS-0.268
- COAGULATION-0.266
- TNFA_SIGNALING_VIA_NFKB-0.265
- PANCREAS_BETA_CELLS-0.256
- INFLAMMATORY_RESPONSE-0.217
- ALLOGRAFT_REJECTION-0.213
- MYOGENESIS-0.199
- ANGIOGENESIS-0.188
- UV_RESPONSE_UP-0.184
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934870 | — | — | 0.909 |
| 2 | 4A4E96B0-5AC6-4B7D-AB1C-F814C338589C | — | — | 0.905 |
| 3 | SRR934724 | — | — | 0.904 |
| 4 | 7779D220-647F-4D6C-890B-022208B51F57 | — | — | 0.901 |
| 5 | 1F4B7E2E-E242-410A-AE78-8FC412D3C0A9 | — | — | 0.890 |
| 6 | CBB97C4E-43C7-4257-A85E-1F72BA71EF91 | — | — | 0.886 |
| 7 | DEB3BE77-120D-4EC5-AA7A-4B2952F2C832 | — | — | 0.886 |
| 8 | B7B9B5C1-C11D-47B8-B2F8-A5660AB961C1 | — | — | 0.883 |
| 9 | 63204446-7AA0-40DC-996D-440F4E19AD0F | — | — | 0.883 |
| 10 | 7ACD648E-76FD-4C83-86AA-51F581A0B09C | — | — | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.486 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.479 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.462 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.366 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.363 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.338 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.334 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.303 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.264 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.243 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.239 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.235 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.223 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.208 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.202 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.188 | Inavolisib | — uncovered |
| PEROXISOME | 0.163 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.142 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.139 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.138 | Temsirolimus | — uncovered |